Effects of MS disease-modifying therapies on responses to vaccinations: A review
: Development of long-term immunologic memory relies upon humoral and cellular immune responses. Vaccinations aim to stimulate these responses against pathogens. Several studies have evaluated the impact of multiple sclerosis disease-modifying therapies on immune response to vaccines. Findings from...
Saved in:
| Published in: | Multiple sclerosis and related disorders Vol. 45; p. 102439 |
|---|---|
| Main Authors: | , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Netherlands
Elsevier B.V
01.10.2020
|
| Subjects: | |
| ISSN: | 2211-0348, 2211-0356, 2211-0356 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | : Development of long-term immunologic memory relies upon humoral and cellular immune responses. Vaccinations aim to stimulate these responses against pathogens. Several studies have evaluated the impact of multiple sclerosis disease-modifying therapies on immune response to vaccines. Findings from these studies have important implications for people with multiple sclerosis who require vaccination and are using disease-modifying therapies.
: Searches using PubMed and other engines were conducted in May 2020 to collect studies evaluating the impact of various disease-modifying therapies on immune responses to vaccination.
: Several studies demonstrated preserved immune responses in people treated with beta-interferons to multiple vaccine types. Limited data suggest vaccine responses to be preserved with dimethyl fumarate treatment, as well. Vaccine responses were reduced to varying degrees in those treated with glatiramer acetate, teriflunomide, sphingosine-1-phosphate receptor modulators, and natalizumab. The timing of vaccination played an important role in those treated with alemtuzumab. Humoral vaccine responses were significantly impaired by B cell depleting anti-CD20 monoclonal antibody therapies, particularly to a neoantigen. Data are lacking on vaccine responses in patients with multiple sclerosis taking cladribine and high-dose corticosteroids. Notably, the majority of these studies have focused on humoral responses, with few examining cellular immune responses to vaccination.
: Prior investigations into the effects of individual disease-modifying therapies on immune responses to existing vaccines can serve as a guide to expected responses to a SARS-CoV-2 vaccine. Responses to any vaccination depend on the vaccine type, the type of response (recall versus response to a novel antigen), and the impact of the individual disease-modifying therapy on humoral and cellular immunity in response to that vaccine type. When considering a given therapy, clinicians should weigh its efficacy against MS for the individual patient versus potential impact on responses to vaccinations that may be needed in the future. |
|---|---|
| AbstractList | Development of long-term immunologic memory relies upon humoral and cellular immune responses. Vaccinations aim to stimulate these responses against pathogens. Several studies have evaluated the impact of multiple sclerosis disease-modifying therapies on immune response to vaccines. Findings from these studies have important implications for people with multiple sclerosis who require vaccination and are using disease-modifying therapies.
Searches using PubMed and other engines were conducted in May 2020 to collect studies evaluating the impact of various disease-modifying therapies on immune responses to vaccination.
Several studies demonstrated preserved immune responses in people treated with beta-interferons to multiple vaccine types. Limited data suggest vaccine responses to be preserved with dimethyl fumarate treatment, as well. Vaccine responses were reduced to varying degrees in those treated with glatiramer acetate, teriflunomide, sphingosine-1-phosphate receptor modulators, and natalizumab. The timing of vaccination played an important role in those treated with alemtuzumab. Humoral vaccine responses were significantly impaired by B cell depleting anti-CD20 monoclonal antibody therapies, particularly to a neoantigen. Data are lacking on vaccine responses in patients with multiple sclerosis taking cladribine and high-dose corticosteroids. Notably, the majority of these studies have focused on humoral responses, with few examining cellular immune responses to vaccination.
Prior investigations into the effects of individual disease-modifying therapies on immune responses to existing vaccines can serve as a guide to expected responses to a SARS-CoV-2 vaccine. Responses to any vaccination depend on the vaccine type, the type of response (recall versus response to a novel antigen), and the impact of the individual disease-modifying therapy on humoral and cellular immunity in response to that vaccine type. When considering a given therapy, clinicians should weigh its efficacy against MS for the individual patient versus potential impact on responses to vaccinations that may be needed in the future. : Development of long-term immunologic memory relies upon humoral and cellular immune responses. Vaccinations aim to stimulate these responses against pathogens. Several studies have evaluated the impact of multiple sclerosis disease-modifying therapies on immune response to vaccines. Findings from these studies have important implications for people with multiple sclerosis who require vaccination and are using disease-modifying therapies. : Searches using PubMed and other engines were conducted in May 2020 to collect studies evaluating the impact of various disease-modifying therapies on immune responses to vaccination. : Several studies demonstrated preserved immune responses in people treated with beta-interferons to multiple vaccine types. Limited data suggest vaccine responses to be preserved with dimethyl fumarate treatment, as well. Vaccine responses were reduced to varying degrees in those treated with glatiramer acetate, teriflunomide, sphingosine-1-phosphate receptor modulators, and natalizumab. The timing of vaccination played an important role in those treated with alemtuzumab. Humoral vaccine responses were significantly impaired by B cell depleting anti-CD20 monoclonal antibody therapies, particularly to a neoantigen. Data are lacking on vaccine responses in patients with multiple sclerosis taking cladribine and high-dose corticosteroids. Notably, the majority of these studies have focused on humoral responses, with few examining cellular immune responses to vaccination. : Prior investigations into the effects of individual disease-modifying therapies on immune responses to existing vaccines can serve as a guide to expected responses to a SARS-CoV-2 vaccine. Responses to any vaccination depend on the vaccine type, the type of response (recall versus response to a novel antigen), and the impact of the individual disease-modifying therapy on humoral and cellular immunity in response to that vaccine type. When considering a given therapy, clinicians should weigh its efficacy against MS for the individual patient versus potential impact on responses to vaccinations that may be needed in the future. Development of long-term immunologic memory relies upon humoral and cellular immune responses. Vaccinations aim to stimulate these responses against pathogens. Several studies have evaluated the impact of multiple sclerosis disease-modifying therapies on immune response to vaccines. Findings from these studies have important implications for people with multiple sclerosis who require vaccination and are using disease-modifying therapies.BACKGROUNDDevelopment of long-term immunologic memory relies upon humoral and cellular immune responses. Vaccinations aim to stimulate these responses against pathogens. Several studies have evaluated the impact of multiple sclerosis disease-modifying therapies on immune response to vaccines. Findings from these studies have important implications for people with multiple sclerosis who require vaccination and are using disease-modifying therapies.Searches using PubMed and other engines were conducted in May 2020 to collect studies evaluating the impact of various disease-modifying therapies on immune responses to vaccination.METHODSSearches using PubMed and other engines were conducted in May 2020 to collect studies evaluating the impact of various disease-modifying therapies on immune responses to vaccination.Several studies demonstrated preserved immune responses in people treated with beta-interferons to multiple vaccine types. Limited data suggest vaccine responses to be preserved with dimethyl fumarate treatment, as well. Vaccine responses were reduced to varying degrees in those treated with glatiramer acetate, teriflunomide, sphingosine-1-phosphate receptor modulators, and natalizumab. The timing of vaccination played an important role in those treated with alemtuzumab. Humoral vaccine responses were significantly impaired by B cell depleting anti-CD20 monoclonal antibody therapies, particularly to a neoantigen. Data are lacking on vaccine responses in patients with multiple sclerosis taking cladribine and high-dose corticosteroids. Notably, the majority of these studies have focused on humoral responses, with few examining cellular immune responses to vaccination.RESULTSSeveral studies demonstrated preserved immune responses in people treated with beta-interferons to multiple vaccine types. Limited data suggest vaccine responses to be preserved with dimethyl fumarate treatment, as well. Vaccine responses were reduced to varying degrees in those treated with glatiramer acetate, teriflunomide, sphingosine-1-phosphate receptor modulators, and natalizumab. The timing of vaccination played an important role in those treated with alemtuzumab. Humoral vaccine responses were significantly impaired by B cell depleting anti-CD20 monoclonal antibody therapies, particularly to a neoantigen. Data are lacking on vaccine responses in patients with multiple sclerosis taking cladribine and high-dose corticosteroids. Notably, the majority of these studies have focused on humoral responses, with few examining cellular immune responses to vaccination.Prior investigations into the effects of individual disease-modifying therapies on immune responses to existing vaccines can serve as a guide to expected responses to a SARS-CoV-2 vaccine. Responses to any vaccination depend on the vaccine type, the type of response (recall versus response to a novel antigen), and the impact of the individual disease-modifying therapy on humoral and cellular immunity in response to that vaccine type. When considering a given therapy, clinicians should weigh its efficacy against MS for the individual patient versus potential impact on responses to vaccinations that may be needed in the future.CONCLUSIONSPrior investigations into the effects of individual disease-modifying therapies on immune responses to existing vaccines can serve as a guide to expected responses to a SARS-CoV-2 vaccine. Responses to any vaccination depend on the vaccine type, the type of response (recall versus response to a novel antigen), and the impact of the individual disease-modifying therapy on humoral and cellular immunity in response to that vaccine type. When considering a given therapy, clinicians should weigh its efficacy against MS for the individual patient versus potential impact on responses to vaccinations that may be needed in the future. AbstractBackground: Development of long-term immunologic memory relies upon humoral and cellular immune responses. Vaccinations aim to stimulate these responses against pathogens. Several studies have evaluated the impact of multiple sclerosis disease-modifying therapies on immune response to vaccines. Findings from these studies have important implications for people with multiple sclerosis who require vaccination and are using disease-modifying therapies. Methods: Searches using PubMed and other engines were conducted in May 2020 to collect studies evaluating the impact of various disease-modifying therapies on immune responses to vaccination. Results: Several studies demonstrated preserved immune responses in people treated with beta-interferons to multiple vaccine types. Limited data suggest vaccine responses to be preserved with dimethyl fumarate treatment, as well. Vaccine responses were reduced to varying degrees in those treated with glatiramer acetate, teriflunomide, sphingosine-1-phosphate receptor modulators, and natalizumab. The timing of vaccination played an important role in those treated with alemtuzumab. Humoral vaccine responses were significantly impaired by B cell depleting anti-CD20 monoclonal antibody therapies, particularly to a neoantigen. Data are lacking on vaccine responses in patients with multiple sclerosis taking cladribine and high-dose corticosteroids. Notably, the majority of these studies have focused on humoral responses, with few examining cellular immune responses to vaccination. Conclusions: Prior investigations into the effects of individual disease-modifying therapies on immune responses to existing vaccines can serve as a guide to expected responses to a SARS-CoV-2 vaccine. Responses to any vaccination depend on the vaccine type, the type of response (recall versus response to a novel antigen), and the impact of the individual disease-modifying therapy on humoral and cellular immunity in response to that vaccine type. When considering a given therapy, clinicians should weigh its efficacy against MS for the individual patient versus potential impact on responses to vaccinations that may be needed in the future. |
| ArticleNumber | 102439 |
| Author | Ciotti, John Robert Cross, Anne Haney Valtcheva, Manouela V. |
| Author_xml | – sequence: 1 givenname: John Robert orcidid: 0000-0002-5696-8841 surname: Ciotti fullname: Ciotti, John Robert email: ciottij@wustl.edu – sequence: 2 givenname: Manouela V. surname: Valtcheva fullname: Valtcheva, Manouela V. – sequence: 3 givenname: Anne Haney orcidid: 0000-0003-0829-7569 surname: Cross fullname: Cross, Anne Haney |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32769063$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUl1rFDEUDVKxtfYXCDKPvsyaj0lmolgopVWholB9Dtnkps06k2yT2ZX9981066IF2bzk65xzL-fcl-ggxAAIvSZ4RjAR7xazIetkZxTT6YU2TD5DR5QSUmPGxcHu3HSH6CTnBS5LcNII8gIdMtoKiQU7Qt8vnAMz5iq66ut1ZX0GnaEeovVu48NNNd5C0ksPBRGqBHkZQy6XMVZrbYwPevTl5X11Vj7XHn6_Qs-d7jOcPO7H6OflxY_zz_XVt09fzs-uasOFGGtuCLONFUxaAs7ipjEAndPMUN4SzVjprpWa6rnmILmxWs41FVIKyhwBxo7R6VZ3uZoPYA2EMeleLZMfdNqoqL369yf4W3UT16plkvOuKwJvHwVSvFtBHtXgs4G-1wHiKqtiKeloS1pZoG_-rrUr8sfGAmBbgEkx5wRuByFYTXmphXrIS015qW1ehSWfsIwfH_wsDft-D_fjlgvF4-J7Utl4CAasTyVPZaPfwz99wje9D97o_hdsIC_iKoUSnyIqU4XV9TRN0zBRzHCZokngw_8F9pa_B8552vw |
| CitedBy_id | crossref_primary_10_1016_j_msard_2022_103486 crossref_primary_10_1177_13524585211069068 crossref_primary_10_3389_fimmu_2021_781843 crossref_primary_10_1038_s41582_022_00646_5 crossref_primary_10_3389_fimmu_2022_1050183 crossref_primary_10_1212_CPJ_0000000000001088 crossref_primary_10_1016_j_ncl_2023_06_001 crossref_primary_10_1007_s40120_022_00394_0 crossref_primary_10_1136_jnnp_2023_331770 crossref_primary_10_1016_j_pharp_2025_09_001 crossref_primary_10_1007_s12035_021_02450_6 crossref_primary_10_1002_rmv_2309 crossref_primary_10_1016_j_msard_2022_103995 crossref_primary_10_1016_j_ebiom_2021_103636 crossref_primary_10_1016_j_msard_2021_103415 crossref_primary_10_1159_000519582 crossref_primary_10_1177_20552173231218117 crossref_primary_10_1111_ane_13453 crossref_primary_10_1177_20552173221085242 crossref_primary_10_1007_s42399_020_00504_9 crossref_primary_10_1007_s00415_022_11009_x crossref_primary_10_1111_jns_12435 crossref_primary_10_3390_vaccines10020279 crossref_primary_10_1186_s12879_025_11083_2 crossref_primary_10_3390_vaccines9101140 crossref_primary_10_3390_vaccines9020099 crossref_primary_10_1007_s00415_024_12518_7 crossref_primary_10_4049_jimmunol_2101142 crossref_primary_10_1016_j_msard_2021_103153 crossref_primary_10_1007_s00415_025_13010_6 crossref_primary_10_3390_jpm12050677 crossref_primary_10_1111_ene_16015 crossref_primary_10_1016_j_msard_2023_104965 crossref_primary_10_1111_cts_13256 crossref_primary_10_1016_j_msard_2022_103737 crossref_primary_10_1016_j_msard_2021_102859 crossref_primary_10_1007_s15005_021_2009_2 crossref_primary_10_3390_vaccines9070773 crossref_primary_10_1007_s13311_021_01165_9 crossref_primary_10_1097_01_NPR_0000000000000202 crossref_primary_10_3389_fimmu_2021_718895 crossref_primary_10_1002_ana_26065 crossref_primary_10_1186_s12883_021_02421_3 crossref_primary_10_1016_j_msard_2022_103561 crossref_primary_10_1016_j_brainres_2021_147459 crossref_primary_10_3389_fped_2021_790159 crossref_primary_10_1016_j_jocn_2021_05_063 crossref_primary_10_30565_medalanya_1443962 crossref_primary_10_1007_s40120_021_00288_7 crossref_primary_10_1093_ofid_ofad349 crossref_primary_10_1212_NXI_0000000000200069 crossref_primary_10_3390_cells14080606 crossref_primary_10_7759_cureus_75889 crossref_primary_10_1186_s12865_024_00628_w crossref_primary_10_1016_j_ejpn_2021_06_002 crossref_primary_10_1097_WCO_0000000000000940 crossref_primary_10_2147_BTT_S267273 crossref_primary_10_1016_j_msard_2022_104125 crossref_primary_10_3389_fneur_2022_828616 crossref_primary_10_3390_brainsci11070890 crossref_primary_10_3389_fimmu_2021_813957 crossref_primary_10_1016_j_msard_2021_102800 crossref_primary_10_1177_13524585231185246 crossref_primary_10_1016_j_neurol_2022_09_006 crossref_primary_10_1007_s11910_021_01117_y crossref_primary_10_1212_CON_0000000000001170 crossref_primary_10_2147_ITT_S240890 crossref_primary_10_4103_1673_5374_346539 crossref_primary_10_1080_21645515_2022_2099171 crossref_primary_10_1097_WCO_0000000000000929 crossref_primary_10_1007_s00415_021_10958_z crossref_primary_10_1080_1744666X_2021_1886924 crossref_primary_10_1177_20552173221087357 crossref_primary_10_1016_j_neurol_2022_11_003 crossref_primary_10_3389_fimmu_2021_701752 crossref_primary_10_1016_j_msard_2021_103225 crossref_primary_10_3389_fimmu_2023_1254128 crossref_primary_10_1016_j_neurot_2023_e00307 crossref_primary_10_7705_biomedica_6366 crossref_primary_10_1007_s00011_021_01446_1 crossref_primary_10_1007_s40120_023_00448_x crossref_primary_10_1007_s11910_024_01355_w crossref_primary_10_3390_vaccines10060977 crossref_primary_10_5005_jp_journals_10071_24399 crossref_primary_10_1177_13524585211003476 crossref_primary_10_1007_s40263_021_00804_1 crossref_primary_10_1177_20552173231191170 crossref_primary_10_1177_13524585221089540 crossref_primary_10_1177_17562864211019598 crossref_primary_10_1007_s40120_023_00565_7 crossref_primary_10_1515_znc_2022_0092 crossref_primary_10_3390_ctn7010006 crossref_primary_10_3390_en14238144 crossref_primary_10_3389_fdgth_2021_803315 crossref_primary_10_1097_01_NT_0000767172_75591_74 crossref_primary_10_1007_s13311_021_01008_7 crossref_primary_10_1111_ene_15809 crossref_primary_10_4103_aian_aian_205_23 crossref_primary_10_4274_tnd_2023_62592 |
| Cites_doi | 10.1179/1743132812Y.0000000059 10.1146/annurev-cellbio-100616-060718 10.1016/j.jns.2014.03.035 10.1016/j.jns.2011.10.013 10.1093/cid/cit816 10.1056/NEJM200102013440501 10.1212/WNL.56.7.938 10.1001/jama.2014.16946 10.1212/WNL.0000000000007035 10.1177/1352458513513970 10.1212/WNL.0b013e3182a35215 10.1002/art.25034 10.1093/ofid/ofy174 10.1086/338043 10.1002/ana.22352 10.1001/jamaneurol.2014.2633 10.1212/NXI.0000000000000409 10.1016/j.msard.2019.04.004 10.1038/nrneurol.2012.8 10.1212/WNL.48.2.312 10.1212/01.wnl.0000188901.12700.e0 10.1212/WNL.0000000000001302 10.1371/journal.pone.0078532 10.1212/NXI.0000000000000398 10.1007/s00415-016-8263-4 10.1212/WNL.0b013e31829e6fbf 10.1111/cns.13034 10.1212/NXI.0000000000000070 10.1111/ene.13537 10.4103/0974-777X.77299 10.1128/CVI.00613-15 10.7326/0003-4819-92-4-471 |
| ContentType | Journal Article |
| Copyright | 2020 Elsevier B.V. Elsevier B.V. Copyright © 2020 Elsevier B.V. All rights reserved. 2020 Elsevier B.V. All rights reserved. 2020 Elsevier B.V. |
| Copyright_xml | – notice: 2020 Elsevier B.V. – notice: Elsevier B.V. – notice: Copyright © 2020 Elsevier B.V. All rights reserved. – notice: 2020 Elsevier B.V. All rights reserved. 2020 Elsevier B.V. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1016/j.msard.2020.102439 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2211-0356 |
| EndPage | 102439 |
| ExternalDocumentID | PMC7395588 32769063 10_1016_j_msard_2020_102439 S2211034820305149 1_s2_0_S2211034820305149 |
| Genre | Journal Article Review |
| GroupedDBID | --- --K --M .1- .FO .~1 0R~ 1P~ 1~. 1~5 4.4 457 4G. 53G 5VS 7-5 8P~ AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AATTM AAXKI AAXLA AAXUO AAYWO ABBQC ABCQJ ABGSF ABJNI ABMAC ABMZM ABTEW ABUDA ABWVN ABXDB ACDAQ ACGFS ACIEU ACLOT ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADMUD ADNMO ADUVX AEBSH AEHWI AEIPS AEKER AENEX AEUPX AEVXI AFJKZ AFPUW AFRHN AFTJW AFXIZ AGHFR AGUBO AGWIK AGYEJ AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX APXCP AXJTR BKOJK BLXMC BNPGV EBS EFJIC EFKBS EFLBG EJD FDB FEDTE FIRID FNPLU FYGXN GBLVA HVGLF HZ~ KOM M41 MO0 MOBAO O-L O9- OAUVE OP~ P-8 P-9 PC. Q38 ROL SDF SEL SPCBC SSH SSN SSU SSZ T5K Z5R ~G- ~HD AACTN AFKWA AJOXV AMFUW RIG AADPK AAIAV ABLVK ABYKQ AJBFU DOVZS LCYCR AAYXX CITATION AGCQF AGRNS CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c566t-5c13d4d639d1efd044cee8fa3c2571a3306379a2aba5e95cda9ba2699623f1e33 |
| ISICitedReferencesCount | 108 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000582230900081&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2211-0348 2211-0356 |
| IngestDate | Tue Sep 30 16:00:00 EDT 2025 Sat Sep 27 19:28:31 EDT 2025 Mon Jul 21 05:58:37 EDT 2025 Wed Nov 05 20:58:31 EST 2025 Tue Nov 18 22:35:25 EST 2025 Fri Feb 23 02:47:36 EST 2024 Sun Feb 23 10:19:59 EST 2025 Tue Oct 14 19:31:09 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Keywords | Disease-modifying therapies Multiple sclerosis Vaccines |
| Language | English |
| License | Copyright © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c566t-5c13d4d639d1efd044cee8fa3c2571a3306379a2aba5e95cda9ba2699623f1e33 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0003-0829-7569 0000-0002-5696-8841 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC7395588 |
| PMID | 32769063 |
| PQID | 2431827179 |
| PQPubID | 23479 |
| PageCount | 1 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7395588 proquest_miscellaneous_2431827179 pubmed_primary_32769063 crossref_primary_10_1016_j_msard_2020_102439 crossref_citationtrail_10_1016_j_msard_2020_102439 elsevier_sciencedirect_doi_10_1016_j_msard_2020_102439 elsevier_clinicalkeyesjournals_1_s2_0_S2211034820305149 elsevier_clinicalkey_doi_10_1016_j_msard_2020_102439 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-10-01 |
| PublicationDateYYYYMMDD | 2020-10-01 |
| PublicationDate_xml | – month: 10 year: 2020 text: 2020-10-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Netherlands |
| PublicationPlace_xml | – name: Netherlands |
| PublicationTitle | Multiple sclerosis and related disorders |
| PublicationTitleAlternate | Mult Scler Relat Disord |
| PublicationYear | 2020 |
| Publisher | Elsevier B.V |
| Publisher_xml | – name: Elsevier B.V |
| References | Briggs, Rozek, Migdal (bib0035) 1980; 92 Flanagan, Fink, Plebanski, Klein (bib0005) 2017; 33 Clem A.S.Fundamentals of vaccine immunology. In: J. Glob. Infect. Dis.. Vol 3.; 2011:73–78. doi:10.4103/0974-777X.77299. Zacour, Ward, Brewer (bib0004) 2016; 23 Lebrun, Vukusic (bib0015) 2019; 31 Kappos, Mehling, Arroyo (bib0028) 2015; 84 Metze, Winkelmann, Loebermann (bib0025) 2019; 25 ACIP Altered Immunocompetence Guidelines for Immunizations | Recommendations | CDC. Miller, Morgante, Buchwald (bib0009) 1997; 48 Langer-Gould, Qian, Tartof (bib0013) 2014; 71 OCEBM Levels of Evidence - CEBM. Stokmaier, Winthrop, Chognot (bib0032) 2018; 90 Scheller, Svanström, Pasternak (bib0010) 2015; 313 Bar-Or, Freedman, Kremenchutzky (bib0020) 2013; 81 Von Hehn, Howard, Liu (bib0024) 2018; 5 Moriabadi, Niewiesk, Kruse (bib0008) 2001; 56 Bar-Or, Wiendl, Miller (bib0026) 2015; 2 Lahood, Emerson, Kumar, Sorensen (bib0036) 1993; 70 Bingham, Looney, Deodhar (bib0033) 2010; 62 Stratton, Ford, Rusch, Clayton (bib0007) 2012 Loebermann, Winkelmann, Hartung, Hengel, Reisinger, Zettl (bib0017) 2012; 8 Ufer, Shakeri-Nejad, Gardin (bib0029) 2017; 4 Wallin L., Quintilio W., Locatelli F., Cassel A., Silva M.B., Skare T.L. Safety and efficiency of influenza vaccination in systemic lupus erythematosus patients. Acta Reumatol. Port.. 34(3):498–502. Olberg, Cox, Nostbakken, Aarseth, Vedeler, Myhr (bib0022) 2014; 20 Rubin, Levin, Ljungman (bib0039) 2013; 58 Schwid, Decker, Lopez-Bresnahan (bib0019) 2005; 65 Kaufman, Pardo, Rossman, Sweetser, Forrestal, Duda (bib0031) 2014; 341 Draft landscape of COVID-19 candidate vaccines. Accessed June26, 2020. Mehling, Hilbert, Fritz (bib0027) 2011; 69 Auriel, Gadoth, Regev, Karni (bib0011) 2012; 314 Confavreux, Suissa, Saddier, Bourdes, Vukusic (bib0012) 2001; 344 Ayling, Vedhara, Fairclough (bib0003) 1781; 2018 . Mehling, Fritz, Hafner (bib0021) 2013; 8 Mailand, Frederiksen (bib0006) 2017; 264 McCarthy, Tuohy, Compston, Kumararatne, Coles, Jones (bib0034) 2013; 81 Wallin, Culpepper, Campbell (bib0001) 2019; 92 Olberg, Eide, Cox (bib0023) 2018; 25 Elkayam, Paran, Caspi (bib0037) 2002; 34 Vågberg, Kumlin, Svenningsson (bib0030) 2012; 34 Epstein, Dunn, Deresinski (bib0016) 2018; 5 Mailand (10.1016/j.msard.2020.102439_bib0006) 2017; 264 Moriabadi (10.1016/j.msard.2020.102439_bib0008) 2001; 56 Olberg (10.1016/j.msard.2020.102439_bib0022) 2014; 20 Mehling (10.1016/j.msard.2020.102439_bib0027) 2011; 69 Rubin (10.1016/j.msard.2020.102439_bib0039) 2013; 58 Bar-Or (10.1016/j.msard.2020.102439_bib0020) 2013; 81 Scheller (10.1016/j.msard.2020.102439_bib0010) 2015; 313 Loebermann (10.1016/j.msard.2020.102439_bib0017) 2012; 8 Bingham (10.1016/j.msard.2020.102439_bib0033) 2010; 62 10.1016/j.msard.2020.102439_bib0014 Metze (10.1016/j.msard.2020.102439_bib0025) 2019; 25 Elkayam (10.1016/j.msard.2020.102439_bib0037) 2002; 34 Miller (10.1016/j.msard.2020.102439_bib0009) 1997; 48 Ayling (10.1016/j.msard.2020.102439_bib0003) 1781; 2018 Ufer (10.1016/j.msard.2020.102439_bib0029) 2017; 4 Briggs (10.1016/j.msard.2020.102439_bib0035) 1980; 92 10.1016/j.msard.2020.102439_bib0018 Schwid (10.1016/j.msard.2020.102439_bib0019) 2005; 65 Kappos (10.1016/j.msard.2020.102439_bib0028) 2015; 84 Bar-Or (10.1016/j.msard.2020.102439_bib0026) 2015; 2 Flanagan (10.1016/j.msard.2020.102439_bib0005) 2017; 33 10.1016/j.msard.2020.102439_bib0038 Kaufman (10.1016/j.msard.2020.102439_bib0031) 2014; 341 Lahood (10.1016/j.msard.2020.102439_bib0036) 1993; 70 Mehling (10.1016/j.msard.2020.102439_bib0021) 2013; 8 Stratton (10.1016/j.msard.2020.102439_bib0007) 2012 Stokmaier (10.1016/j.msard.2020.102439_bib0032) 2018; 90 Zacour (10.1016/j.msard.2020.102439_bib0004) 2016; 23 Lebrun (10.1016/j.msard.2020.102439_bib0015) 2019; 31 Olberg (10.1016/j.msard.2020.102439_bib0023) 2018; 25 McCarthy (10.1016/j.msard.2020.102439_bib0034) 2013; 81 10.1016/j.msard.2020.102439_bib0002 Vågberg (10.1016/j.msard.2020.102439_bib0030) 2012; 34 10.1016/j.msard.2020.102439_bib0040 Auriel (10.1016/j.msard.2020.102439_bib0011) 2012; 314 Wallin (10.1016/j.msard.2020.102439_bib0001) 2019; 92 Langer-Gould (10.1016/j.msard.2020.102439_bib0013) 2014; 71 Epstein (10.1016/j.msard.2020.102439_bib0016) 2018; 5 Confavreux (10.1016/j.msard.2020.102439_bib0012) 2001; 344 Von Hehn (10.1016/j.msard.2020.102439_bib0024) 2018; 5 |
| References_xml | – volume: 341 start-page: 22 year: 2014 end-page: 27 ident: bib0031 article-title: Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis publication-title: J. Neurol. Sci. – volume: 92 start-page: E1029 year: 2019 end-page: E1040 ident: bib0001 article-title: The prevalence of MS in the United States: a population-based estimate using health claims data publication-title: Neurology – volume: 84 start-page: 872 year: 2015 end-page: 879 ident: bib0028 article-title: Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis publication-title: Neurology – volume: 31 start-page: 173 year: 2019 end-page: 188 ident: bib0015 article-title: Immunization and multiple sclerosis: recommendations from the French multiple sclerosis society publication-title: Mult. Scler. Relat. Disord. – volume: 81 start-page: 872 year: 2013 end-page: 876 ident: bib0034 article-title: Immune competence after alemtuzumab treatment of multiple sclerosis publication-title: Neurology – volume: 20 start-page: 1074 year: 2014 end-page: 1080 ident: bib0022 article-title: Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study publication-title: Mult. Scler. J. – volume: 25 start-page: 245 year: 2019 end-page: 254 ident: bib0025 article-title: Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies publication-title: CNS Neurosci. Ther. – volume: 4 start-page: e398 year: 2017 ident: bib0029 article-title: Impact of siponimod on vaccination response in a randomized, placebo-controlled study publication-title: Neurol. Neuroimmunol. neuroinflammation – volume: 8 start-page: 143 year: 2012 end-page: 151 ident: bib0017 article-title: Vaccination against infection in patients with multiple sclerosis publication-title: Nat. Rev. Neurol. – volume: 34 start-page: 147 year: 2002 end-page: 153 ident: bib0037 article-title: Immunogenicity and Safety of Pneumococcal Vaccination in Patients with Rheumatoid Arthritis or Systemic Lupus Erythematosus publication-title: Clin. Infect Dis. – volume: 48 start-page: 312 year: 1997 end-page: 314 ident: bib0009 article-title: A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis publication-title: Neurology – volume: 8 year: 2013 ident: bib0021 article-title: Preserved antigen-specific immune response in patients with multiple sclerosis responding to IFNβ-therapy publication-title: PLoS ONE – reference: Draft landscape of COVID-19 candidate vaccines. Accessed June26, 2020. – volume: 2018 start-page: 327 year: 1781 end-page: 340 ident: bib0003 article-title: Measuring vaccine responses in the multiplex era. publication-title: Methods in Molecular Biology – volume: 23 start-page: 236 year: 2016 end-page: 242 ident: bib0004 article-title: Standardization of Hemagglutination Inhibition Assay for Influenza Serology Allows for High Reproducibility between Laboratories publication-title: Clin. Vaccine Immunol. – volume: 92 start-page: 471 year: 1980 end-page: 477 ident: bib0035 article-title: Influenza vaccination in kidney transplant recipients: cellular and humoral immune responses publication-title: Ann. Intern. Med. – volume: 5 year: 2018 ident: bib0024 article-title: Immune response to vaccines is maintained in patients treated with dimethyl fumarate publication-title: Neurol. Neuroimmunol. NeuroInflammation. – volume: 90 year: 2018 ident: bib0032 article-title: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis (S36.002) publication-title: Neurology – reference: ACIP Altered Immunocompetence Guidelines for Immunizations | Recommendations | CDC. – volume: 34 start-page: 730 year: 2012 end-page: 733 ident: bib0030 article-title: Humoral immune response to influenza vaccine in natalizumab-treated MS patients publication-title: Neurol. Res. – reference: Wallin L., Quintilio W., Locatelli F., Cassel A., Silva M.B., Skare T.L. Safety and efficiency of influenza vaccination in systemic lupus erythematosus patients. Acta Reumatol. Port.. 34(3):498–502. – volume: 62 start-page: 64 year: 2010 end-page: 74 ident: bib0033 article-title: Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial publication-title: Arthritis Rheum. – volume: 70 start-page: 289 year: 1993 end-page: 294 ident: bib0036 article-title: Antibody levels and response to pneumococcal vaccine in steroid-dependent asthma publication-title: Ann. Allergy – volume: 313 start-page: 54 year: 2015 end-page: 61 ident: bib0010 article-title: Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system publication-title: JAMA – volume: 65 start-page: 1964 year: 2005 end-page: 1966 ident: bib0019 article-title: Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a publication-title: Neurology – year: 2012 ident: bib0007 article-title: Adverse Effects of Vaccines: Evidence and Causality – volume: 264 start-page: 1035 year: 2017 end-page: 1050 ident: bib0006 article-title: Vaccines and multiple sclerosis: a systematic review publication-title: J. Neurol. – reference: . – volume: 5 year: 2018 ident: bib0016 article-title: Infectious Complications of Multiple Sclerosis Therapies: implications for Screening, Prophylaxis, and Management publication-title: Open forum Infect. Dis. – volume: 33 start-page: 577 year: 2017 end-page: 599 ident: bib0005 article-title: Sex and Gender Differences in the Outcomes of Vaccination over the Life Course publication-title: Annu. Rev. Cell Dev. Biol. – volume: 25 start-page: 527 year: 2018 end-page: 534 ident: bib0023 article-title: Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy publication-title: Eur J Neurol – volume: 71 start-page: 1506 year: 2014 end-page: 1513 ident: bib0013 article-title: Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases publication-title: JAMA Neurol. – volume: 69 start-page: 408 year: 2011 end-page: 413 ident: bib0027 article-title: Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients publication-title: Ann. Neurol. – reference: Clem A.S.Fundamentals of vaccine immunology. In: J. Glob. Infect. Dis.. Vol 3.; 2011:73–78. doi:10.4103/0974-777X.77299. – volume: 81 start-page: 552 year: 2013 end-page: 558 ident: bib0020 article-title: Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis publication-title: Neurology – volume: 314 start-page: 102 year: 2012 end-page: 103 ident: bib0011 article-title: Seasonal and H1N1v influenza vaccines in MS: safety and compliance publication-title: J. Neurol. Sci. – reference: OCEBM Levels of Evidence - CEBM. – volume: 58 start-page: 309 year: 2013 end-page: 318 ident: bib0039 article-title: IDSA clinical practice guideline for vaccination of the immunocompromised host publication-title: Clin. Infect. Dis. – volume: 56 start-page: 938 year: 2001 end-page: 943 ident: bib0008 article-title: Influenza vaccination in MS: absence of T-cell response against white matter proteins publication-title: Neurology – volume: 344 start-page: 319 year: 2001 end-page: 326 ident: bib0012 article-title: Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group publication-title: N. Engl. J. Med. – volume: 2 start-page: e70 year: 2015 ident: bib0026 article-title: Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens publication-title: Neurol. Neuroimmunol. NeuroInflammation – volume: 34 start-page: 730 issue: 7 year: 2012 ident: 10.1016/j.msard.2020.102439_bib0030 article-title: Humoral immune response to influenza vaccine in natalizumab-treated MS patients publication-title: Neurol. Res. doi: 10.1179/1743132812Y.0000000059 – volume: 33 start-page: 577 issue: 1 year: 2017 ident: 10.1016/j.msard.2020.102439_bib0005 article-title: Sex and Gender Differences in the Outcomes of Vaccination over the Life Course publication-title: Annu. Rev. Cell Dev. Biol. doi: 10.1146/annurev-cellbio-100616-060718 – volume: 341 start-page: 22 issue: 1–2 year: 2014 ident: 10.1016/j.msard.2020.102439_bib0031 article-title: Natalizumab treatment shows no clinically meaningful effects on immunization responses in patients with relapsing-remitting multiple sclerosis publication-title: J. Neurol. Sci. doi: 10.1016/j.jns.2014.03.035 – volume: 314 start-page: 102 issue: 1–2 year: 2012 ident: 10.1016/j.msard.2020.102439_bib0011 article-title: Seasonal and H1N1v influenza vaccines in MS: safety and compliance publication-title: J. Neurol. Sci. doi: 10.1016/j.jns.2011.10.013 – ident: 10.1016/j.msard.2020.102439_bib0038 – volume: 58 start-page: 309 issue: 3 year: 2013 ident: 10.1016/j.msard.2020.102439_bib0039 article-title: IDSA clinical practice guideline for vaccination of the immunocompromised host publication-title: Clin. Infect. Dis. doi: 10.1093/cid/cit816 – volume: 344 start-page: 319 issue: 5 year: 2001 ident: 10.1016/j.msard.2020.102439_bib0012 article-title: Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group publication-title: N. Engl. J. Med. doi: 10.1056/NEJM200102013440501 – volume: 56 start-page: 938 issue: 7 year: 2001 ident: 10.1016/j.msard.2020.102439_bib0008 article-title: Influenza vaccination in MS: absence of T-cell response against white matter proteins publication-title: Neurology doi: 10.1212/WNL.56.7.938 – volume: 313 start-page: 54 issue: 1 year: 2015 ident: 10.1016/j.msard.2020.102439_bib0010 article-title: Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system publication-title: JAMA doi: 10.1001/jama.2014.16946 – volume: 90 issue: 15 Supplement year: 2018 ident: 10.1016/j.msard.2020.102439_bib0032 article-title: Effect of Ocrelizumab on Vaccine Responses in Patients With Multiple Sclerosis (S36.002) publication-title: Neurology – volume: 92 start-page: E1029 issue: 10 year: 2019 ident: 10.1016/j.msard.2020.102439_bib0001 article-title: The prevalence of MS in the United States: a population-based estimate using health claims data publication-title: Neurology doi: 10.1212/WNL.0000000000007035 – volume: 20 start-page: 1074 issue: 8 year: 2014 ident: 10.1016/j.msard.2020.102439_bib0022 article-title: Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study publication-title: Mult. Scler. J. doi: 10.1177/1352458513513970 – volume: 81 start-page: 872 issue: 10 year: 2013 ident: 10.1016/j.msard.2020.102439_bib0034 article-title: Immune competence after alemtuzumab treatment of multiple sclerosis publication-title: Neurology doi: 10.1212/WNL.0b013e3182a35215 – volume: 62 start-page: 64 issue: 1 year: 2010 ident: 10.1016/j.msard.2020.102439_bib0033 article-title: Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial publication-title: Arthritis Rheum. doi: 10.1002/art.25034 – year: 2012 ident: 10.1016/j.msard.2020.102439_bib0007 – volume: 5 issue: 8 year: 2018 ident: 10.1016/j.msard.2020.102439_bib0016 article-title: Infectious Complications of Multiple Sclerosis Therapies: implications for Screening, Prophylaxis, and Management publication-title: Open forum Infect. Dis. doi: 10.1093/ofid/ofy174 – volume: 34 start-page: 147 issue: 2 year: 2002 ident: 10.1016/j.msard.2020.102439_bib0037 article-title: Immunogenicity and Safety of Pneumococcal Vaccination in Patients with Rheumatoid Arthritis or Systemic Lupus Erythematosus publication-title: Clin. Infect Dis. doi: 10.1086/338043 – volume: 69 start-page: 408 issue: 2 year: 2011 ident: 10.1016/j.msard.2020.102439_bib0027 article-title: Antigen-specific adaptive immune responses in fingolimod-treated multiple sclerosis patients publication-title: Ann. Neurol. doi: 10.1002/ana.22352 – volume: 71 start-page: 1506 issue: 12 year: 2014 ident: 10.1016/j.msard.2020.102439_bib0013 article-title: Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases publication-title: JAMA Neurol. doi: 10.1001/jamaneurol.2014.2633 – volume: 5 issue: 1 year: 2018 ident: 10.1016/j.msard.2020.102439_bib0024 article-title: Immune response to vaccines is maintained in patients treated with dimethyl fumarate publication-title: Neurol. Neuroimmunol. NeuroInflammation. doi: 10.1212/NXI.0000000000000409 – volume: 31 start-page: 173 year: 2019 ident: 10.1016/j.msard.2020.102439_bib0015 article-title: Immunization and multiple sclerosis: recommendations from the French multiple sclerosis society publication-title: Mult. Scler. Relat. Disord. doi: 10.1016/j.msard.2019.04.004 – volume: 8 start-page: 143 issue: 3 year: 2012 ident: 10.1016/j.msard.2020.102439_bib0017 article-title: Vaccination against infection in patients with multiple sclerosis publication-title: Nat. Rev. Neurol. doi: 10.1038/nrneurol.2012.8 – ident: 10.1016/j.msard.2020.102439_bib0014 – ident: 10.1016/j.msard.2020.102439_bib0018 – volume: 48 start-page: 312 issue: 2 year: 1997 ident: 10.1016/j.msard.2020.102439_bib0009 article-title: A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis publication-title: Neurology doi: 10.1212/WNL.48.2.312 – volume: 65 start-page: 1964 issue: 12 year: 2005 ident: 10.1016/j.msard.2020.102439_bib0019 article-title: Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a publication-title: Neurology doi: 10.1212/01.wnl.0000188901.12700.e0 – volume: 84 start-page: 872 issue: 9 year: 2015 ident: 10.1016/j.msard.2020.102439_bib0028 article-title: Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis publication-title: Neurology doi: 10.1212/WNL.0000000000001302 – volume: 8 issue: 11 year: 2013 ident: 10.1016/j.msard.2020.102439_bib0021 article-title: Preserved antigen-specific immune response in patients with multiple sclerosis responding to IFNβ-therapy publication-title: PLoS ONE doi: 10.1371/journal.pone.0078532 – volume: 4 start-page: e398 issue: 6 year: 2017 ident: 10.1016/j.msard.2020.102439_bib0029 article-title: Impact of siponimod on vaccination response in a randomized, placebo-controlled study publication-title: Neurol. Neuroimmunol. neuroinflammation doi: 10.1212/NXI.0000000000000398 – volume: 2018 start-page: 327 year: 1781 ident: 10.1016/j.msard.2020.102439_bib0003 article-title: Measuring vaccine responses in the multiplex era. – ident: 10.1016/j.msard.2020.102439_bib0040 – volume: 264 start-page: 1035 issue: 6 year: 2017 ident: 10.1016/j.msard.2020.102439_bib0006 article-title: Vaccines and multiple sclerosis: a systematic review publication-title: J. Neurol. doi: 10.1007/s00415-016-8263-4 – volume: 81 start-page: 552 issue: 6 year: 2013 ident: 10.1016/j.msard.2020.102439_bib0020 article-title: Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis publication-title: Neurology doi: 10.1212/WNL.0b013e31829e6fbf – volume: 25 start-page: 245 issue: 2 year: 2019 ident: 10.1016/j.msard.2020.102439_bib0025 article-title: Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease-modifying therapies publication-title: CNS Neurosci. Ther. doi: 10.1111/cns.13034 – volume: 2 start-page: e70 issue: 2 year: 2015 ident: 10.1016/j.msard.2020.102439_bib0026 article-title: Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens publication-title: Neurol. Neuroimmunol. NeuroInflammation doi: 10.1212/NXI.0000000000000070 – volume: 25 start-page: 527 issue: 3 year: 2018 ident: 10.1016/j.msard.2020.102439_bib0023 article-title: Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy publication-title: Eur J Neurol doi: 10.1111/ene.13537 – ident: 10.1016/j.msard.2020.102439_bib0002 doi: 10.4103/0974-777X.77299 – volume: 23 start-page: 236 issue: 3 year: 2016 ident: 10.1016/j.msard.2020.102439_bib0004 article-title: Standardization of Hemagglutination Inhibition Assay for Influenza Serology Allows for High Reproducibility between Laboratories publication-title: Clin. Vaccine Immunol. doi: 10.1128/CVI.00613-15 – volume: 92 start-page: 471 issue: 4 year: 1980 ident: 10.1016/j.msard.2020.102439_bib0035 article-title: Influenza vaccination in kidney transplant recipients: cellular and humoral immune responses publication-title: Ann. Intern. Med. doi: 10.7326/0003-4819-92-4-471 – volume: 70 start-page: 289 issue: 4 year: 1993 ident: 10.1016/j.msard.2020.102439_bib0036 article-title: Antibody levels and response to pneumococcal vaccine in steroid-dependent asthma publication-title: Ann. Allergy |
| SSID | ssj0000651461 |
| Score | 2.5092545 |
| SecondaryResourceType | review_article |
| Snippet | : Development of long-term immunologic memory relies upon humoral and cellular immune responses. Vaccinations aim to stimulate these responses against... AbstractBackground: Development of long-term immunologic memory relies upon humoral and cellular immune responses. Vaccinations aim to stimulate these... Development of long-term immunologic memory relies upon humoral and cellular immune responses. Vaccinations aim to stimulate these responses against pathogens.... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 102439 |
| SubjectTerms | Betacoronavirus - immunology Coronavirus Infections - immunology Coronavirus Infections - prevention & control COVID-19 COVID-19 Vaccines Disease-modifying therapies Humans Immunocompromised Host - drug effects Immunocompromised Host - immunology Immunosuppressive Agents - therapeutic use Multiple sclerosis Multiple Sclerosis - drug therapy Multiple Sclerosis - immunology Neurology Pandemics - prevention & control Pneumonia, Viral - immunology Pneumonia, Viral - prevention & control Review SARS-CoV-2 Vaccines Viral Vaccines - immunology |
| Title | Effects of MS disease-modifying therapies on responses to vaccinations: A review |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2211034820305149 https://www.clinicalkey.es/playcontent/1-s2.0-S2211034820305149 https://dx.doi.org/10.1016/j.msard.2020.102439 https://www.ncbi.nlm.nih.gov/pubmed/32769063 https://www.proquest.com/docview/2431827179 https://pubmed.ncbi.nlm.nih.gov/PMC7395588 |
| Volume | 45 |
| WOSCitedRecordID | wos000582230900081&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: Elsevier SD Freedom Collection Journals 2021 customDbUrl: eissn: 2211-0356 dateEnd: 20210531 omitProxy: false ssIdentifier: ssj0000651461 issn: 2211-0348 databaseCode: AIEXJ dateStart: 20120101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3bbtMw1Oo2hHhB3CmXyUiIF0jVOE6d8FZVnQbayqR1qG-Wkzhapi4pTVtNfD3HsZ20tIzxwEtU-RKnPhef43ND6D11gzSNEuFEqfAcKqXrCOpHTpqALhH6DCSGqCo2wUajYDIJz1qtnzYWZjVleR7c3ISz_wpqaANgq9DZfwB3_VJogN8AdHgC2OF5J8APGw8NUNKNAca5LpJMhzTpiKtMVnaCuXaR1XkeViKOM307WOqI9XljObBVn6wDYgnLwgmb6RzPVUgMyK6JSeZZS-oD5RGSWadf48htO7-LqUKaldBRQ3mxhNc0brcDW9K9D4fBx2ORGxu0uaQAjdS6uxleRoi6ifV8k_V6R5thxtRf46auSpcY7mT0-s7hqnNdAiF11JKdZvRmWu3RN350cXLCx8PJ-MPsh6MqjinLvCm_socOCPND4IgH_S_Dydf6hg6EM1X0XFUntF9q01ZVDoJbS_9JtNlWXX73wF0TacaP0EOji-C-xqHHqCXzJ-j-qfG2eIrODCrhIsWn53gLlXCNSrjIcY1KeFHgdVT6jPtYI9IzdHE0HA-OHVOBw4lBzF84fux6CU1Aik1cCeRLKchUAVB1DJzeFR7omx4LBRGR8GXox4kII0F6oEMTL3Wl5z1H-3mRy5cIpz3CRODHEQOBMhCq3gulXSmjiDGf0V4bEbt5PDbp6VWVlCm3fohXvNpxrnac6x1vo0_1pJnOznL7cGqhwm3gMRyVHJDq9mls1zRZGqovuctLwrv8XCFKV6WLUseoS2Fmr55pJFotqf59yXcWaTjwe2XEAyIrliWHXjcgDM7RNnqhkaj-6x5hKu-4Bx-8gV71AJVLfrMnzy6rnPLKXu8Hwas7rPsaPWhI_A3aX8yX8i26F68WWTk_RHtsEhwaWvoFHJnrbg |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effects+of+MS+disease-modifying+therapies+on+responses+to+vaccinations%3A+A+review&rft.jtitle=Multiple+sclerosis+and+related+disorders&rft.au=Ciotti%2C+John+Robert&rft.au=Valtcheva%2C+Manouela+V&rft.au=Cross%2C+Anne+Haney&rft.date=2020-10-01&rft.issn=2211-0356&rft.eissn=2211-0356&rft.volume=45&rft.spage=102439&rft_id=info:doi/10.1016%2Fj.msard.2020.102439&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F22110348%2FS2211034820X00071%2Fcov150h.gif |